fbpx Skip to main content

Disparities in SARS-CoV-2 infection rates, treatment access, infection outcomes, and mortality rates have been noted since early in the pandemic. However, the reasons for these disparities consist of a complex mix of factors that can be hard to pin down and may include a combination of environmental, socioeconomic, and genetic factors.

This study, published in the Journal of Internal Medicine, consists of a general analysis of current disparities in COVID-19 outcomes, attempting to go beyond statistical analysis to understand the causal nature of these disparities.

The researcher notes that the racial disparity is very striking and extends into age groups where mortality is overall low, with African American and Latinx patients aged 25-34 exhibiting mortality rates 6.4 times higher than their white counterparts. The research indicates that there are a number of socioeconomic factors that exacerbate racially disparate comorbidities, including grocery mobility and access to high-quality healthcare. 

It is noted that in the absence of any known genetic disparity, the most likely explanation is  that comorbidities are dependent on socioeconomic disparities, especially related to employment, housing, food access, and financial resources, hindering compliance with health guidelines and access to healthcare. The study includes a discussion of genetic factors as well as thorough analyses of other types of disparities.

The study concluded that short of restructuring the allocation of means and eliminating socioeconomic disparities, the best solution is to strategically allocate aid in a way that takes these disparities into account so that they may be dealt with before they become even more severe [1].


[1] Carethers, J. M. (2020). Insights into disparities observed with COVID‐19. Journal of Internal Medicine. https://doi.org/10.1111/joim.13199

You May Also Like::  Culturally Sensitive Care = Meeting Patients Where They Are

“Keeping up with the indications and adverse reactions to immune checkpoint inhibitors can be a full-time job. Cutaneous side effects occur in up to 45% of patients treated with ipilimumab and 34% of patients treated with nivolumab and pembrolizumab.” https://bit.ly/3FGtxtd

.@spfnomt: This month’s #DermWorld article “Estate planning 101” is especially important for young physicians to read. The long, all-consuming years between adolescence and physicianhood can become a blur...https://bit.ly/3FxOtCv

That’s a wrap #AAD2023! 5 days of soaking up knowledge from dermatologists on topics such as hidradenitis, melasma, & dietary triggers of common dermatoses.

I LOVED the #womenshealth focused sessions on vulvar dermatoses and pregnancy medication safety.


New approach uses microbiome to treat skin disease by repairing the injured microbiome that allowed inflammation to flare up in the first place, rather than reducing the inflammation after the fact. https://bit.ly/3Jt6H9v

Load More